CytRx (CYTR) Releases Quarterly Earnings, Misses Estimates By $0.01 EPS
On a related note, analysts at Zacks downgraded shares of CytRx from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, January 9th. They now have a $2.30 price target on the stock.
CytRx (CYTR) opened at 2.46 on Monday. CytRx (CYTR) has a 1-year low of $1.59 and a 1-year high of $5.50. The stock’s 50-day moving average is currently $2.16. The company’s market cap is $74.8 million.
CytRx Corporation as (CytRx) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.